| Family reflections: pediatric aplastic anemia research; a parent perspective |
|
Pediatric Research |
Aplastic Anemia, Pediatric |
| Cost-effectiveness of iptacopan for paroxysmal nocturnal hemoglobinuria |
|
Blood |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Myelodysplastic Syndromes Treatment (PDQ®): Patient Version |
|
PDQ Cancer Information Summaries |
Myelodysplastic Syndromes (MDS) |
| Advances in the management of higher-risk myelodysplastic syndromes: future prospects |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial |
|
The Lancet Haematology |
Myelodysplastic Syndromes (MDS) |
| Phase 3 randomized COMMODORE 2 trial: Crovalimab versus eculizumab in patients with paroxysmal nocturnal hemoglobinuria naive to complement inhibition |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| A growing panoply of options for patients with paroxysmal nocturnal hemoglobinuria |
|
American Journal of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Clinical Outcomes and Healthcare Resource Utilization for Patients With Lower-Risk Myelodysplastic Syndromes Treated With Erythropoiesis-Stimulating Agents |
|
Clinical Lymphoma, Myeloma & Leukemia |
Myelodysplastic Syndromes (MDS) |
